Renal news roundup from AKF

The Food and Drug Administration (FDA) has granted priority review to a supplemental new drug application for finerenone for the treatment of adults with type 1 diabetes (T1D) and chronic kidney disease (CKD). The application is supported by data from a Phase 3 trial, in which fi...

A study in the journal Science Translational Medicine introduces a molecular imaging test that detects kidney fibrosis noninvasively using urine samples. The test, developed by researchers at Sun Yat-sen University and based on biomarkers transglutaminase 2 (TG2) and LysAld, dist...

Mineralys Therapeutics' lorundrostat has shown significant reductions in blood pressure in patients with CKD and hypertension, according to data from the Phase III Launch-HTN trial presented at the European Meeting on Hypertension and Cardiovascular Protection. The drug also redu...

Medtronic's Symplicity Spyral renal denervation system was effective in reducing blood pressure over three years, according to results from the global SYMPLICITY registry. A separate analysis found that the system also was effective in patients with severe hypertension. MassDevic...

GLP-1 receptor agonists can reduce the risk of major adverse cardiovascular events and end-stage kidney disease in patients with T1D without increasing the risk of diabetic ketoacidosis or hypoglycemia, according to a study in Nature Medicine. The analysis of observational data f...

Modest protein restriction in patients with stage 3 and 4 CKD is associated with a reduced risk for adverse clinical outcomes, especially dialysis initiation, without a negative effect on nutritional status, according to a study in JAMA Network Open. The study involved 1,441 pati...

A retrospective analysis of intensive care unit (ICU) cases from 2000 to 2023 found that iodinated contrast media was linked to an increased risk of acute kidney injury (AKI) in neonates who had a computed tomography (CT) or magnetic resonance imaging (MRI) scan, with a rate of 1...

An observational study that included more than 2.5 million patients found that for those ages 40 and older who had a systolic blood pressure of 130 mm Hg to 179 mm Hg, the risk of hospitalization or death due to falls, hypotension, syncope and AKI increased when they began antihy...

Deputy José Calderón, a close friend and colleague of Joseph Vela for 15 years, volunteered to become a living kidney donor after learning about Vela's stage 5 kidney failure diagnosis. Calderón immediately offered to help, stating he did not hesitate because of their strong bond...